{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "19756004",
  "DateCompleted": {
    "Year": "2009",
    "Month": "11",
    "Day": "10"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1038/sj.bjc.6605273"
    ],
    "Journal": {
      "ISSN": "1532-1827",
      "JournalIssue": {
        "Volume": "101 Suppl 1",
        "Issue": "Suppl 1",
        "PubDate": {
          "Year": "2009",
          "Month": "Sep"
        }
      },
      "Title": "British journal of cancer",
      "ISOAbbreviation": "Br J Cancer"
    },
    "ArticleTitle": "Impact of effective prevention and management of febrile neutropenia.",
    "Pagination": {
      "StartPage": "S23",
      "EndPage": "S26",
      "MedlinePgn": "S23-6"
    },
    "Abstract": {
      "AbstractText": [
        "Chemotherapy-induced febrile neutropenia is costly in both financial and human terms. The associated costs can be reduced substantially through the development and implementation of national policies and locally agreed protocols for the prevention and management of febrile neutropenia. Patients, the NHS, healthcare professionals and the broader community all stand to benefit from a commitment to effective management of this common and predictable side effect of some chemotherapy regimens for early-stage breast cancer."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Academic Oncology, Royal Free Hospital, Pond Street, London NW3 2QG, UK. daniel_krell@hotmail.com"
          }
        ],
        "LastName": "Krell",
        "ForeName": "D",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Jones",
        "ForeName": "A L",
        "Initials": "AL"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Br J Cancer",
    "NlmUniqueID": "0370635",
    "ISSNLinking": "0007-0920"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Breast Neoplasms"
    },
    {
      "QualifierName": [
        "chemically induced",
        "prevention & control",
        "therapy"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "chemically induced",
        "prevention & control",
        "therapy"
      ],
      "DescriptorName": "Neutropenia"
    },
    {
      "QualifierName": [],
      "DescriptorName": "State Medicine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "United Kingdom"
    }
  ]
}